M1-aminopeptidase family - beyond antigen-trimming activities.


Journal

Current opinion in immunology
ISSN: 1879-0372
Titre abrégé: Curr Opin Immunol
Pays: England
ID NLM: 8900118

Informations de publication

Date de publication:
08 2023
Historique:
received: 08 12 2022
revised: 07 04 2023
accepted: 11 04 2023
medline: 7 8 2023
pubmed: 23 5 2023
entrez: 22 5 2023
Statut: ppublish

Résumé

Antigen (Ag)-trimming aminopeptidases belong to the oxytocinase subfamily of M1 metallopeptidases. In humans, this subfamily contains the endoplasmic reticulum aminopeptidases 1 and 2 (ERAP1 and 2) and the insulin-responsive aminopeptidase (IRAP, synonym oxytocinase), an endosomal enzyme. The ability of these enzymes to trim antigenic precursors and to generate major histocompatibility class-I ligands has been demonstrated extensively for ERAP1, less for ERAP2, which is absent in rodents, and exclusively in the context of cross-presentation for IRAP. During 20 years of research on these aminopeptidases, their enzymatic function has been very well characterized and their genetic association with autoimmune diseases, cancers, and infections is well established. The mechanisms by which these proteins are associated to human diseases are not always clear. This review discusses the Ag-trimming-independent functions of the oxytocinase subfamily of M1 aminopeptidases and the new questions raised by recent publications on IRAP and ERAP2.

Identifiants

pubmed: 37216842
pii: S0952-7915(23)00056-0
doi: 10.1016/j.coi.2023.102337
pii:
doi:

Substances chimiques

Aminopeptidases EC 3.4.11.-
Cystinyl Aminopeptidase EC 3.4.11.3
Antigens 0
Minor Histocompatibility Antigens 0
ERAP1 protein, human EC 3.4.11.-
ERAP2 protein, human EC 3.4.11.-

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102337

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no conflicts of interest.

Auteurs

Irini Evnouchidou (I)

INSERM U1149, CRI, Centre de Recherche sur l'Inflammation, Paris, France; CNRS ERL8252, Paris, France; Université de Paris, Site Xavier Bichat, Paris, France; Inflamex Laboratory of Excellence, Paris, France; Inovarion, Paris, France.

Despoina Koumantou (D)

INSERM U1149, CRI, Centre de Recherche sur l'Inflammation, Paris, France; CNRS ERL8252, Paris, France; Université de Paris, Site Xavier Bichat, Paris, France; Inflamex Laboratory of Excellence, Paris, France.

Mathilde Nugue (M)

INSERM U1149, CRI, Centre de Recherche sur l'Inflammation, Paris, France; CNRS ERL8252, Paris, France; Université de Paris, Site Xavier Bichat, Paris, France; Inflamex Laboratory of Excellence, Paris, France.

Loredana Saveanu (L)

INSERM U1149, CRI, Centre de Recherche sur l'Inflammation, Paris, France; CNRS ERL8252, Paris, France; Université de Paris, Site Xavier Bichat, Paris, France; Inflamex Laboratory of Excellence, Paris, France. Electronic address: Loredana.saveanu@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH